Fig. 1 · Structure

Documents & Downloads

Nintedanib esylate

Cat. No. A16197 CAS 656247-18-6

RTK inhibitor

Nintedanib is a potent inhibitor of multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs).

In Stock

Publications for Nintedanib esylate

2 publications citing this product

  1. Majid Momeny, .et al. , Eur J Pharmacol, 2020, 882:173298 PMID: 32593665
  2. Thibaut Fourniols, .et al. , Int J Pharm, 2020, Jun 30;584:119337 PMID: 32371002

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In primary IPF lung fibroblasts, nintedanib esylate reduced PDGF- and VEGF-stimulated receptor phosphorylation at 400 nM. Basal FGFR phosphorylation was also downregulated; bFGF did not further enhance it in this model. These are cellular signaling findings rather than isolated-enzyme potency estimates. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
VEGFR1 IC50 34 nM
VEGFR2 IC50 13 nM
VEGFR3 IC50 13 nM
FGFR1 IC50 69 nM
FGFR2 IC50 37 nM
FGFR3 IC50 108 nM
PDGFRα IC50 59 nM
PDGFRβ IC50 65 nM

8 targets · Scroll to view more

Nintedanib esylate Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Nintedanib esylate from 2 published references.

Nintedanib esylate In Vitro Studies

At 1 μM, nintedanib esylate inhibited TGF-β1-stimulated collagen secretion in primary IPF and non-fibrotic lung fibroblasts and collagen deposition in IPF cells after 48 hours. Control-cell collagen deposition was low and showed no significant drug effect. [1]

Receptor phosphorylation in primary IPF lung fibroblasts

Cell-based study · Primary lung fibroblasts from patients with IPF; non-fibrotic donor cells were expression/viability comparators. [1]

Nintedanib reduced ligand-induced PDGFR and VEGFR phosphorylation. FGFR phosphorylation was already high without bFGF and was downregulated with nintedanib; the ligand did not further increase it.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PDGFR and VEGFR phosphorylation relative to total receptorqualitative inhibition Significant inhibition reported (p < 0.05); no numerical IC50 determined here.[1]
FGFR phosphorylationqualitative response High basal phosphorylation; no further enhancement by bFGF; downregulation in the presence of nintedanib.[1]

Literature-Reported Treatment Conditions

Treatment concentration
400 nM
Exposure duration
30-minute pretreatment, followed by 30-minute growth-factor stimulation.
Method
Serum-starved cells were stimulated with PDGF-BB, VEGF or bFGF, each at 10 ng/mL, in separate conditions.
Co-treatment
Growth-factor stimulation; no second pharmacologic inhibitor.
Reported limits
Drug vehicle is not stated in the inspected Materials and methods. This is a cellular phosphorylation endpoint, not an isolated-enzyme IC50.
Methods and source locations

Compound reported in the paper: Nintedanib esylate; Compound label in the paper: Nintedanib (BIBF 1120)

Evidence for the reported nintedanib esylate material in primary lung fibroblasts; no purity, potency or lot-validation claim for A16197.

Materials and methods opening paragraph, Patients and cell culture, Western blotting; Results receptor section; Figure 1A–C

PDGFR and VEGFR phosphorylation relative to total receptor: Western blotting/densitometry; mean ± SEM from three different cell lines. — Figure 1C and Results: The effect of nintedanib on receptor expression and phosphorylation

FGFR phosphorylation: Western blotting; no significance threshold assigned to the FGFR reduction in this record. — Figure 1C and corresponding Results paragraph

TGF-β1-stimulated collagen secretion and deposition

Cell-based study · Primary IPF and non-fibrotic control human lung fibroblasts; four different cell lines per reported collagen experiment. [1]

At 1 μM, nintedanib inhibited TGF-β1-stimulated collagen secretion in IPF and control fibroblasts and collagen deposition in IPF fibroblasts. Control-cell deposition was low and no significant drug effect was reported.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
TGF-β1-induced secretion of collagensqualitative inhibition At 1 μM: inhibition in IPF fibroblasts (p < 0.05) and non-fibrotic control cells (p ≤ 0.05).[1]
TGF-β1-induced collagen depositionqualitative inhibition and limitation At 1 μM: inhibition in IPF fibroblasts (p < 0.05); control-cell deposition was low with no significant nintedanib effect (data not shown by authors).[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.001, 0.01, 0.1 and 1 μM; significant collagen inhibition reported at 1 μM.
Exposure duration
30-minute pretreatment before TGF-β1; 48-hour collagen endpoint.
Method
TGF-β1 5 ng/mL; collagen secretion/deposition assessed by Sircol (collagens I–V).
Co-treatment
TGF-β1 stimulation; no second drug.
Reported limits
Drug vehicle not stated in inspected methods. No exact percent reduction or IC50 inferred from bars.
Methods and source locations

Compound reported in the paper: Nintedanib esylate; Compound label in the paper: Nintedanib (BIBF 1120)

Evidence for the reported nintedanib esylate material in primary lung fibroblasts; no purity, potency or lot-validation claim for A16197.

Materials identity; ECM-deposition and Statistical analysis methods; collagen Results section; Figure 4A–C/caption

TGF-β1-induced secretion of collagens: Sircol assay; mean ± SEM, four different cell lines; each experiment at least in duplicate; control (0.1% FCS) set to 100%. — Figure 4A–B/caption and Results: Growth-factor-induced collagen secretion is inhibited by nintedanib

TGF-β1-induced collagen deposition: Sircol assay; Figure 4C displays IPF cells only; four cell lines, mean ± SEM, at least duplicate experiments. — Figure 4C/caption and corresponding Results paragraph

Nintedanib esylate In Vivo Studies

In an independent bleomycin mouse intervention, oral nintedanib esylate (reported nintedanib dose 60 mg/kg twice daily for 21 days) did not improve lung function, hydroxyproline content or histological fibrosis. This negative result is specific to the reported therapeutic model; the authors did not measure lung drug exposure. [2]

Therapeutic nintedanib in the second bleomycin mouse intervention

Animal study · Adult male C57BL/6J-family mice with single-dose bleomycin-induced lung fibrosis; source Study 2. Healthy vehicle controls and bleomycin vehicle controls were included. [2]

Study 2 did not show improvement in spirometric lung function, hydroxyproline content or histological fibrosis with oral nintedanib. This model-specific negative result does not establish lack of efficacy in human IPF.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
FEV0.1, FVC, inspiratory capacity and static compliancequalitative negative result No improvement with nintedanib relative to bleomycin vehicle controls.[2]
Lung hydroxyproline and histological fibrosis/inflammationqualitative negative result No improvement in hydroxyproline, Ashcroft score, MT/PSR staining or Gal-3 staining in Study 2.[2]

Conditions shared by the study groups

Route
Oral (PO)
Frequency
Twice daily (BID)
Treatment course
21 days; start day 8 after bleomycin per Methods 2.4.
Vehicle
Source Methods 2.4: initially 0.1% natrosol, then HCl/methylcellulose/water dilution; final component proportions are not completely specified.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Study 2 nintedanib
60 mg/kg (reported nintedanib dose; mass basis not further specified)
Vehicle-dosed bleomycin mice and healthy saline/vehicle controls. Methods describe initial n = 18 per bleomycin group and n = 10 healthy controls; these are not asserted as endpoint-specific analysed n.No improvement in the selected functional, hydroxyproline and histological endpoints.[2]
Study 2 nintedanib
Model: Male bleomycin-treated C57BL/6J-family mice
Reported limits: Exact eligibility thresholds/timing conflict within the article; endpoint-specific final n and explicit salt/base dose convention are not established.
Methods and source locations

Compound reported in the paper: Nintedanib esylate; Compound label in the paper: Nintedanib (MedKoo #100944)

A negative result for the reported esylate reagent under this mouse intervention; no universal antifibrotic or clinical claim.

Methods 2.1–2.12 (excluding RNA-seq detail); Results 3.1–3.4; Figure 1B; Figures 2–4 Study 2; Discussion limitations

FEV0.1, FVC, inspiratory capacity and static compliance: Terminal flexiVent spirometry; Figure 3 Study 2 columns; mean ± SEM. Healthy-control values demonstrated the disease-associated impairment. — Methods 2.6, 2.12; Results 3.2; Figure 3A–D, Study 2

Lung hydroxyproline and histological fibrosis/inflammation: Hydroxyproline colorimetry; GHOST Ashcroft scoring and whole-section histomorphometry; mean ± SEM. — Methods 2.9–2.10, 2.12; Results 3.1, 3.3; Figure 2E and Figure 4B–F, Study 2

Study 2 nintedanib · Methods 2.2–2.6, 2.9–2.10; Figure 1B; Figures 2E, 3A–D and 4B–F Study 2

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 656247-18-6
Applications RTK inhibitor
Formula C33H39N5O7S
Molecular Weight 649.76
Synonyms BIBF-1120 esylate
SMILES
O=C(C1=CC(NC/2=O)=C(C=C1)C2=C(NC3=CC=C(N(C)C(CN4CCN(C)CC4)=O)C=C3)/C5=CC=CC=C5)OC.CCS(=O)(O)=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 89 mg/mL (136.97 mM)
Water 89 mg/mL (136.97 mM)
Ethanol 4 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Nintedanib esylate Research References

  1. [1] Katrin E Hostettler, Jun Zhong, Eleni Papakonstantinou, et al. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Respiratory Research (2014). PMID: 25496490 DOI: 10.1186/s12931-014-0157-3 Source material
  2. [2] Jamal Bousamaki, Grzegorz Maciag, Asbjørn Graver Petersen, et al. Nintedanib Lacks Efficacy in a Spirometry‐Confirmed and Bleomycin‐Induced Mouse Model of Idiopathic Pulmonary Fibrosis Basic & Clinical Pharmacology & Toxicology (2026). PMID: 41826148 DOI: 10.1111/bcpt.70220 Source material

Publications

2 publications citing this product

  1. Majid Momeny, .et al. , Eur J Pharmacol, 2020, 882:173298 PMID: 32593665
  2. Thibaut Fourniols, .et al. , Int J Pharm, 2020, Jun 30;584:119337 PMID: 32371002

Added to your cart

View Cart Checkout
Loading...